PolarityTE wants to eliminate skin grafts with its platform of regenerative technology. The Utah-based biotech is still new to the industry, but co-founders Denver Lough and Ned Swanson are betting that their company can take on the clinical standard of care for wound management.
“No other product, whether it be a drug, a biologic device, or a cell therapy type of product has been able to regenerate full thickness hair-bearing skin,” Lough, who serves as the company’s chairman, CEO, president & chief scientific officer, told Drug Delivery Business News.
The two former Johns Hopkins residents have grown their company to include more than 80 employees in the last year. PolarityTE is in the middle of a limited market roll-out for SkinTE – doctors are using the product for burn reconstruction and to address acute and chronic wounds.
The company, which Lough said is “waging war on skin grafts”, wants to create technologies that can tackle the array of problems that crop up when doctors use skin grafts.
Get the full story at our sister site, Drug Delivery Business News.
